Neurofit Supplies 'Neurofit Aqua' to Public Medical Centers Including National Medical Center

[Asia Economy Reporter Jang Hyowon] Neurophyt, a specialized company in brain disease imaging artificial intelligence (AI) solutions, has begun expanding its domestic sales by supplying its main brain imaging analysis product to public medical centers in Korea for the first time.

On the 30th, Neurophyt announced that, supported by the Public Procurement Service's innovative product pilot purchase project, it supplied the degenerative brain disease diagnostic guide software 'Neurophyt AQUA' to four domestic public medical centers. The public medical centers supplied with Neurophyt AQUA are ▲National Medical Center ▲Seosan Medical Center ▲Cheonan Medical Center ▲Mokpo City Medical Center.

Neurophyt AQUA was designated as an innovative product by the Public Procurement Service in September last year and registered in the Innovation Market. As an innovative product, Neurophyt AQUA can be supplied to public institutions through negotiated contracts for three years from the date of designation. Additionally, it received opportunities to be matched with institutions wishing to purchase and use innovative products with the Public Procurement Service budget and to directly test the product in the public market.

Neurophyt AQUA is a brain imaging analysis medical device software that analyzes brain MRI (magnetic resonance imaging) using AI technology to assess brain atrophy and white matter degeneration observed in neurodegenerative diseases such as Alzheimer's disease and vascular dementia.

Neurophyt AQUA, Neurophyt's representative brain disease diagnostic solution, boasts a high analysis accuracy with a clinically confirmed analysis failure rate of approximately 0%. While existing brain imaging analysis software takes about 8 to 24 hours for brain image segmentation, Neurophyt AQUA can segment and analyze brain images in just 5 minutes. It provides quantitative results of brain image analysis, greatly assisting radiologists in clinical diagnosis.

In 2020, Neurophyt AQUA obtained Class 2 medical device certification from the Korean Ministry of Food and Drug Safety. To enter overseas markets, it acquired European CE certification last year and medical device certification from Japan's Ministry of Health, Labour and Welfare (MHLW) in March.

As multiple public medical centers have adopted Neurophyt AQUA, recognizing the product's excellence externally, Neurophyt plans to accelerate its domestic market strategy by strengthening sales targeting tertiary general hospitals, university hospitals, and health screening centers.

Bin Jungil, CEO of Neurophyt, said, "Having completed product advancement, Neurophyt AQUA is currently conducting post-market clinical trials jointly with tertiary general hospitals and large hospitals to obtain Class 3 medical device approval from the Ministry of Food and Drug Safety." He added, "The substantive review by the U.S. Food and Drug Administration (FDA) for Neurophyt AQUA is underway, and we plan to enter the U.S. market, the world's largest medical device market."

He emphasized, "With the increase in dementia patients due to the global aging era, Neurophyt AQUA, an early diagnostic support solution for brain diseases, is expected to be widely used in domestic and international markets."

This content was produced with the assistance of AI translation services.